Dr. Gozani founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as Chairman of the Board of Directors and as President and Chief Executive Officer. Dr. Gozani has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 4 million patients have benefited from the Company’s technology over the past 20 years.
Dr. Gozani is an expert in non-invasive neurostimulation. He received his M.D. degree from Harvard Medical School and the Harvard-MIT Division of Health Science and Technology. Dr. Gozani earned his Ph.D. in Neurobiology, M.S. in Electrical Engineering & Computer Science and B.A. in Computer Science from the University of California at Berkeley. Following his studies, Dr. Gozani conducted post-doctoral research at Harvard Medical School and MIT. He holds over 50 U.S. and international patents and has authored over 30 articles in scientific and clinical peer-reviewed journals.
Tom Higgins brings to NeuroMetrix a broad set of financial management and operations skills from his experience with publicly traded companies in life sciences, specialty chemicals and financial services. He has extensive international experience with a particular emphasis on Japan, Southeast Asia and the Middle East.
Prior to joining NeuroMetrix, Tom was Executive Vice President and Chief Financial Officer at Caliper Life Sciences. Inc, a provider of technology and services for life sciences research. Before Caliper, Tom was Executive Vice President, Operations and Chief Financial Officer at V.I. Technologies, Inc. (“Vitex”), a biotechnology company addressing blood safety. Before Vitex, Tom served at Cabot Corporation in various senior finance and operations roles. His last position at Cabot was President of Distrigas of Massachusetts Corporation, a subsidiary involved in the liquefied natural gas business, and prior to that he was responsible for Cabot’s Asia Pacific carbon black operations. Before joining Cabot, Tom was with PricewaterhouseCoopers where he started his career.
Tom holds a B.B.A. with honors from Boston University.
Ms. Bell brings to the company over 20 years of sales, business development and strategy experience in the Medicare Advantage sector, and more generally in population health. Ms. Bell was most recently at eHealth, Inc., where she was Senior Director, Value Based Provider Partnerships. In this role, she was responsible for building partnerships with the largest and most innovative Medicare Advantage plans and at-risk provider networks. Prior to that role, Ms. Bell was Chief Growth Officer at Cecelia Health where she was responsible for building the company's chronic disease management business. Ms. Bell has also held senior roles at CareCentrix, Inc., ZeOmega, Inc., Bosch Healthcare, and VITAS Healthcare. She holds a Bachelor's degree in Nursing from the University of Manitoba and is licensed as a registered nurse.
Xuan Kong joined the company in 1999. In his role of Chief Data Scientist, he leads the company’s data science initiative by leveraging the data assets collected from Company’s products to deliver personalized and clinically optimized pain relief and health experience for customers. In addition, he provides leadership and technology contributions for the Company's basic research and product development functions. Xuan also manages the Company's intellectual property portfolio. He has published numerous papers in leading signal processing, biomedical engineering, and clinical neurophysiology journals. Xuan has been awarded twenty U.S. and foreign patents.
Prior to joining the company, Xuan was a tenured associate professor in the Department of Electrical Engineering at Northern Illinois University (Dekalb, IL). As a principal investigator, he successfully led many federally and industrially funded projects in signal processing research and bio-electric signal analysis applications.
Xuan received his Ph.D. from The Johns Hopkins University and MBA from Boston University. He is certified as professional risk manager by PRMIA. He is a senior member of IEEE and a member of Eta Kappa Nu and Beta Gamma Sigma.
Ms. Damkier brings to NeuroMetrix over two decades of healthcare and technology experience working in both the Medicare and Commercial sector. Prior to joining NeuroMetrix, Ms. Damkier was at eHealth, Inc., as Director of Value Based Partnerships. While at eHealth, Ms. Damkier was responsible for the successful growth of new partnerships securing relationships with the largest care delivery organizations in the United States. Ms. Damkier has held senior business development roles at CareCentrix, Inc., NTT DATA, Inc., Cardinal Health, Inc., and Allscripts, Inc.
Ms. Damkier holds a B.A. from the University of California at San Diego – Eleanor Roosevelt College.
Mr. Harmel brings 15 years of experience in high growth medical technology and device sales, including building and managing successful sales teams on a national scale. Mr. Harmel was most recently the U.S. Director of Market Development at Neurolief, which developed and is commercializing a wearable neuromodulation device for migraine.
Prior to Neurolief, Mr. Harmel was Regional Director of Business Development for Neuronetics, which markets a transcranial magnetic stimulation (TMS) device for the treatment of major depression. Before that, he held sales leadership roles at Virgin Pulse, CDx Diagnostics and Avantis Medical Systems.
Dr. Peskin is currently serving in an advisory role to several companies in life sciences, medical device industry, and physician services organizations. Up until August 2022 he was the Executive Medical Director, Population Health at Horizon Blue Cross Blue Shield of New Jersey. His expertise encompasses physician leadership, population health management, clinical and operational performance improvement in health care, medical education and scientific communications. He has been one of the driving forces for the creation of and successful maturation of value-based models in New Jersey.
Dr. Peskin is an Associate Clinical Professor in the Department of Medicine at Rutgers Robert Wood Johnson Medical School. He is a clinical preceptor at The Eric B. Chandler Clinic for interns and residents in Internal Medicine. Dr. Peskin assists with the Population Health and business of medicine training for the Rutgers RWJ Internal Medicine physicians in training. Dr. Peskin was advanced to Master of the American College of Physicians in 2020.
Dr. Peskin received his bachelor’s degree from The University of North Carolina Chapel Hill and medical degree from Emory University School of Medicine. He completed residency at Saint Elizabeth’s Medical Center in Boston and holds an MBA from the Sloan School of Management at Massachusetts Institute of Technology.